NCT05174000View on ClinicalTrials.gov

BE of Euthyrox® Tablets (Merck Nantong Versus Merck Darmstadt Sites)

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

January 10, 2022

Primary Completion Date

October 18, 2022

Study Completion Date

October 18, 2022

Conditions
Healthy
Interventions
DRUG

Test Euthyrox®

Participants will receive single oral dose of Test Euthyrox® either in treatment period 1, 2, 3 or 4.

DRUG

Reference Euthyrox®

Participants will receive single oral dose of Reference Euthyrox® either in treatment period 1, 2, 3 or 4.

Trial Locations (1)

Unknown

Xuanwu Hospital, Capital Medical University, Beijing

All Listed Sponsors
lead

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

INDUSTRY